Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.

mBio - 26 Sept 2017

Li Zhihai, Wang Daning, Gu Ying, Song Shuo, He Maozhou, Shi Jingjie, Liu Xinlin, Wei Shuangping, Li Jinjin, Yu Hai, Zheng Qingbing, Yan Xiaodong, Baker Timothy S, Zhang Jun, McLellan Jason S, Li Shaowei, Xia Ningshao

Abstract excerpt

Persistent, high-risk human papillomavirus (HPV) infection is the primary cause of cervical cancer. Neutralizing antibodies elicited by L1-only virus-like particles (VLPs) can block HPV infection; however, the lack of high-resolution structures has limited our understanding of the mode of virus infection and the requirement for type specificity at the molecular level. Here, we describe two antibodies, A12A3 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigen-Antibody Complex

Share to Crystallography, X-Ray

Share to Epitopes

Share to Mutagenesis

Share to Papillomaviridae

Share to Papillomavirus Infections

Source

Open in PubMed Open full text

Identifiers

PMID: 28951471
DOI: 10.1128/mBio.00787-17
PMCID: PMC5615192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.PMID 28951471Read ↗

Functional assessment and structural basis of antibody binding to human papillomavirus capsidSemantic proximity Read ↗

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.Semantic proximity Read ↗

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificitySemantic proximity Read ↗

Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralizationSemantic proximity Read ↗

High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16Semantic proximity Read ↗

Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58Semantic proximity Read ↗

HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopesSemantic proximity Read ↗

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.Semantic proximity Read ↗

Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibodySemantic proximity Read ↗

Neutralization of Human Papillomavirus (HPV) Pseudovirions: A Novel and Efficient Approach to Detect and Characterize HPV Neutralizing AntibodiesSemantic proximity Read ↗

Hybrid Papillomavirus L1 Molecules Assemble into Virus-like Particles That Reconstitute Conformational Epitopes and Induce Neutralizing Antibodies to Distinct HPV TypesSemantic proximity Read ↗

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.